BBI-001
Hereditary Hemochromatosis (Iron Overload)
Phase 1Active
Key Facts
About Bond Biosciences
Bond Biosciences is an early-stage biotech developing non-absorbed oral polymers to sequester excess dietary ions in the GI tract, preventing systemic absorption and related diseases. Its lead candidate, BBI-001, targets Hereditary Hemochromatosis, a genetic iron overload disorder with no FDA-approved pharmacologic therapy, positioning it to address a significant unmet need. The company, founded in 2021, is led by a team with strong backgrounds in drug development, corporate strategy, and venture capital, and is backed by a seed round from its co-founders. Its platform technology holds potential for expansion into other ion-related disorders.
View full company profile